344 related articles for article (PubMed ID: 28205376)
1. Drug-drug interactions in pediatric oncology patients.
Balk TE; van der Sijs IH; van Gelder T; Janssen JJB; van der Sluis IM; van Leeuwen RWF; Engels FK
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28205376
[TBL] [Abstract][Full Text] [Related]
2. Identifying high risk medications causing potential drug-drug interactions in outpatients: A prescription database study based on an online surveillance system.
Toivo TM; Mikkola JA; Laine K; Airaksinen M
Res Social Adm Pharm; 2016; 12(4):559-68. PubMed ID: 26459026
[TBL] [Abstract][Full Text] [Related]
3. Potential drug-drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factors.
Fernández de Palencia Espinosa MÁ; Díaz Carrasco MS; Alonso Romero JL; de la Rubia Nieto A; Espuny Miró A
Int J Clin Pharm; 2015 Dec; 37(6):1021-7. PubMed ID: 26391788
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two databases to detect potential drug-drug interactions between prescriptions of HIV/AIDS patients in critical care.
Ramos GV; Guaraldo L; Japiassú AM; Bozza FA
J Clin Pharm Ther; 2015 Feb; 40(1):63-7. PubMed ID: 25329640
[TBL] [Abstract][Full Text] [Related]
5. Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer: A Prospective Study of Medication Surveillance.
Ramos-Esquivel A; Víquez-Jaikel Á; Fernández C
J Oncol Pract; 2017 Jul; 13(7):e613-e622. PubMed ID: 28628392
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoepidemiological study of drug-drug interactions in onco-hematological pediatric patients.
Fernández de Palencia Espinosa MA; Díaz Carrasco MS; Fuster Soler JL; Ruíz Merino G; De la Rubia Nieto MA; Espuny Miró A
Int J Clin Pharm; 2014 Dec; 36(6):1160-9. PubMed ID: 25204258
[TBL] [Abstract][Full Text] [Related]
7. Clinically relevant potential drug-drug interactions among outpatients: A nationwide database study.
Jazbar J; Locatelli I; Horvat N; Kos M
Res Social Adm Pharm; 2018 Jun; 14(6):572-580. PubMed ID: 28716467
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital.
Ramasubbu SK; Mahato SK; Agnihotri A; Pasricha RK; Nath UK; Das B
Cancer Treat Res Commun; 2021; 26():100277. PubMed ID: 33348276
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of clinically manifested drug interactions in hospitalized patients: A systematic review and meta-analysis.
Gonzaga de Andrade Santos TN; Mendonça da Cruz Macieira G; Cardoso Sodré Alves BM; Onozato T; Cunha Cardoso G; Ferreira Nascimento MT; Saquete Martins-Filho PR; Pereira de Lyra D; Oliveira Filho AD
PLoS One; 2020; 15(7):e0235353. PubMed ID: 32609783
[TBL] [Abstract][Full Text] [Related]
10. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis.
Zheng WY; Richardson LC; Li L; Day RO; Westbrook JI; Baysari MT
Eur J Clin Pharmacol; 2018 Jan; 74(1):15-27. PubMed ID: 29058038
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions.
van Leeuwen RWF; Jansman FGA; van den Bemt PMLA; de Man F; Piran F; Vincenten I; Jager A; Rijneveld AW; Brugma JD; Mathijssen RHJ; van Gelder T
Ann Oncol; 2015 May; 26(5):992-997. PubMed ID: 25628444
[TBL] [Abstract][Full Text] [Related]
12. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis.
Dechanont S; Maphanta S; Butthum B; Kongkaew C
Pharmacoepidemiol Drug Saf; 2014 May; 23(5):489-97. PubMed ID: 24616171
[TBL] [Abstract][Full Text] [Related]
13. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study.
Kim SH; Suh Y; Ah YM; Jun K; Lee JY
Support Care Cancer; 2020 Aug; 28(8):3617-3626. PubMed ID: 31802250
[TBL] [Abstract][Full Text] [Related]
14. Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases.
Suriyapakorn B; Chairat P; Boonyoprakarn S; Rojanarattanangkul P; Pisetcheep W; Hunsakunachai N; Vivithanaporn P; Wongwiwatthananukit S; Khemawoot P
PLoS One; 2019; 14(11):e0225239. PubMed ID: 31725785
[TBL] [Abstract][Full Text] [Related]
15. Potential drug-drug interactions in paediatric outpatient prescriptions in Nigeria and implications for the future.
Oshikoya KA; Oreagba IA; Godman B; Oguntayo FS; Fadare J; Orubu S; Massele A; Senbanjo IO
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1505-1515. PubMed ID: 27592636
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software.
Nightingale G; Pizzi LT; Barlow A; Barlow B; Jacisin T; McGuire M; Swartz K; Chapman A
J Geriatr Oncol; 2018 Sep; 9(5):526-533. PubMed ID: 29510896
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy.
Gagne JJ; Maio V; Rabinowitz C
J Clin Pharm Ther; 2008 Apr; 33(2):141-51. PubMed ID: 18315779
[TBL] [Abstract][Full Text] [Related]
18. Countrywide prevalence of critical drug interactions in Hungarian outpatients: a retrospective analysis of pharmacy dispensing data.
Somogyi-Végh A; Ludányi Z; Erdős Á; Botz L
BMC Pharmacol Toxicol; 2019 May; 20(1):36. PubMed ID: 31151485
[TBL] [Abstract][Full Text] [Related]
19. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists.
Chan A; Tan SH; Wong CM; Yap KY; Ko Y
Clin Ther; 2009; 31 Pt 2():2379-86. PubMed ID: 20110047
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of potential drug-drug interactions in Swedish pediatric outpatients.
Holm J; Eiermann B; Kimland E; Mannheimer B
PLoS One; 2019; 14(8):e0220685. PubMed ID: 31381591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
